• In February 2026, a Philadelphia jury found Johnson & Johnson liable for its talc-based baby powder contributing to a woman’s ovarian cancer death, awarding US$50,000 in compensatory and US$200,000 in punitive damages amid more than 70,000 similar lawsuits pending nationwide.
• This verdict, alongside recent scientific findings strengthening the evidence of a link between genital talc use and ovarian cancer, intensifies Johnson & Johnson’s legal and reputational risk at a time when it has already halted global talc-based powder sales.
• We’ll now examine how this talc liability verdict, alongside thousands of similar pending cases, may reshape Johnson & Johnson’s investment narrative.

Find 54 companies with promising cash flow potential yet trading below their fair value.

Johnson & Johnson Investment Narrative Recap

To own Johnson & Johnson today, you need to believe its broad Innovative Medicine and MedTech engines can offset patent expiries and legal overhangs, while funding dividends and R&D. In the near term, talc litigation looks like the most important risk to that story, and this Philadelphia verdict, alongside 70,000-plus similar cases, reinforces that concern. By contrast, the main positive catalyst remains execution on the late stage drug and device pipeline.

Against that backdrop, the recent OMNY-AF and VARIPULSE data matter because they highlight progress in higher growth cardiovascular electrophysiology, an area many analysts already see as a key earnings driver. Early AFib results with the investigational OMNYPULSE platform and reassuring safety data for VARIPULSE support the view that MedTech could help cushion legal, pricing, and loss of exclusivity pressures, even as the talc cases keep near term legal costs and reputational questions in focus.

But while the product pipeline may look encouraging, the scale and uncertainty of talc related legal exposure is something investors should be aware of...

Johnson & Johnson's narrative projects $104.1 billion revenue and $22.9 billion earnings by 2028. This requires 4.7% yearly revenue growth and a modest $0.2 billion earnings increase from $22.7 billion today.

Uncover how Johnson & Johnson's forecasts yield a $231.25 fair value, a 5% downside to its current price.

Exploring Other Perspectives

Before this verdict, the most optimistic analysts were assuming Johnson & Johnson could reach about US$115.7 billion in revenue and US$26.2 billion in earnings by 2029, which is far more upbeat than consensus and leans on rapid MedTech expansion and a very broad drug portfolio, yet both that view and the more cautious risk focus on long term legal exposure may need to be revisited in light of how talc outcomes evolve from here.

Explore 18 other fair value estimates on Johnson & Johnson - why the stock might be worth as much as 57% more than the current price!

Build Your Own Johnson & Johnson Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Johnson & Johnson research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Johnson & Johnson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Johnson & Johnson's overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.